A practical reference on incretin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-17. Anything still debated is marked as such rather than presented as settled.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
=== Preparative mass spectrometry === The primary function of mass spectrometry is as a tool for chemical analyses based on detection and quantification of ions according to their mass-to-charge ratio. However, mass spectrometry also shows promise for material synthesis. Ion soft landing is characterized by deposition of intact species on surfaces at low kinetic energies which precludes the fragmentation of the incident species. The soft landing technique was first reported in 1977 for the reaction of low energy sulfur containing ions on a lead surface.
=== Animals and aquaculture === Various studies on spirulina as an alternative feed for animal and aquaculture have been done. Spirulina can be fed up to 10% for poultry and less than 4% for quail. An increase in spirulina content up to 40 g/kg (0.64 oz/lb) for 16 days in 21-day-old broiler male chicks resulted in yellow and red coloration of flesh, possibly due to the accumulation of the yellow pigment zeaxanthin. Pigs and rabbits can receive up to 10% of the feed and increase in the spirulina content in cattle resulted in increase in milk yield and weight. Spirulina has been established as an alternative feedstock and immune booster for bigmouth buffalo, milk fish, cultured striped jack, carp, red sea bream, tilapia, catfish, yellow tail, zebrafish, shrimp, and abalone, and up to 2% spirulina per day in aquaculture feed can be safely recommended.
A smart insulin patch, also known as a glucose-responsive insulin patch, is a type of wearable medical device for diabetes treatment. It is a transdermal patch comprising glucose-sensitive microneedle-array loaded with insulin for blood glucose regulation. Once applied on the skin, the microneedles penetrate under the skin and can sense blood sugar levels. If glucose levels go up, it can promote the release of insulin, which is transported through the regional lymph and capillary vessels for glucose regulation.
Sources: en.wikipedia.org
== Clinical significance == Many diseases are the result of a homeostatic failure. Almost any homeostatic component can malfunction either as a result of an inherited defect, an inborn error of metabolism, or an acquired disease. Some homeostatic mechanisms have inbuilt redundancies, which ensures that life is not immediately threatened if a component malfunctions; but sometimes a homeostatic malfunction can result in serious disease, which can be fatal if not treated. A well-known example of a homeostatic failure is shown in type 1 diabetes mellitus. Here blood sugar regulation is unable to function because the beta cells of the pancreatic islets are destroyed and cannot produce the necessary insulin. The blood sugar rises in a condition known as hyperglycemia. The plasma ionized calcium homeostat can be disrupted by the constant, unchanging, over-production of parathyroid hormone by a parathyroid adenoma resulting in the typically features of hyperparathyroidism, namely high plasma ionized Ca2+ levels and the resorption of bone, which can lead to spontaneous fractures. The abnormally high plasma ionized calcium concentrations cause conformational changes in many cell-surface proteins (especially ion channels and hormone or neurotransmitter receptors) giving rise to lethargy, muscle weakness, anorexia, constipation and labile emotions. The body water homeostat can be compromised by the inability to secrete ADH in response to even the normal daily water losses via the exhaled air, the feces, and insensible sweating.
=== Electricity and Wi-Fi === In August 2002, Starbucks provided free Wi-Fi in the United Kingdom, although in the past, a Starbucks rewards card was required. On July 1, 2010, Starbucks offered free Wi-Fi in all of its stores in the U.S. and Canada. In August 2010, Starbucks began offering free Wi-Fi in Germany via BT Openzone. In October 2012, Starbucks and Duracell Powermat announced a pilot program to install Powermat charging surfaces in the tabletops in selected Starbucks stores in the Boston area. Furthermore, Starbucks announced its support in the Power Matters Alliance (PMA) and its membership in the PMA board, along with Google and AT&T, in an effort to create "a real-world ecosystem of wireless power" through a universal wireless charging standard that customers could use to recharge smartphones. In 2013, it switched providers in the U.S. from AT&T to Google. In August 2016, startup company FluxPort introduced Qi inductive charging pads at select locations in Germany.
== Medical career == Farthing began his medical career in New Zealand where he practiced as a dermatologist. After five years, he moved abroad and worked for a year in Riyadh, Saudi Arabia. He then moved to England and joined St. Stephen's Hospital, London in Chelsea. Between 1985 and 1987, the numbers of AIDS patients treated at St Stephen's rose from a dozen to over 1000. From 1985 to 1988, he was involved in clinical trials for the antiretroviral drugs Thymosin, AZT and foscarnet. In 1987, he helped found the Kobler Center at St Stephen's Hospital which specialised in the treatment and research of HIV/AIDS. It was one of the first wards in the United Kingdom to specialise in the area. He was chair of the all-party parliamentary committee on AIDS during the late 1980s, and was instrumental in guiding the governments reaction to the AIDS crisis. In 1988, he was awarded a Churchill fellowship which allowed him to move to the United States of America where he studied AIDS at the Bellevue Hospital in New York. He later became the director of the hospital's AIDS treatment program. In 1994, he moved to Los Angeles where he became the principal investigator of the AIDS Healthcare Foundation, and in 2001, he was promoted to medical director. In 2007, he left the United States for Hong Kong where he joined Merck Sharp & Dohme. At the time of his death, he was director of medical affairs for infectious diseases in the Asia-Pacific.
Flutamide has been used to prevent the effects of the testosterone flare at the start of GnRH agonist therapy in men with prostate cancer. The combination of flutamide with an estrogen such as ethinylestradiol sulfonate has been used as a form of combined androgen blockade and as an alternative to the combination of flutamide with surgical or medical castration.
Sources: en.wikipedia.org
=== Classification methods === Classification methods use data to train a program (classifier) to distinguish positive examples of interacting protein/domain pairs with negative examples of non-interacting pairs. Popular classifiers used are Random Forest Decision (RFD) and Support Vector Machines. RFD produces results based on the domain composition of interacting and non-interacting protein pairs. When given a protein pair to classify, RFD first creates a representation of the protein pair in a vector. The vector contains all the domain types used to train RFD, and for each domain type the vector also contains a value of 0, 1, or 2. If the protein pair does not contain a certain domain, then the value for that domain is 0. If one of the proteins of the pair contains the domain, then the value is 1. If both proteins contain the domain, then the value is 2. Using training data, RFD constructs a decision forest, consisting of many decision trees. Each decision tree evaluates several domains, and based on the presence or absence of interactions in these domains, makes a decision as to if the protein pair interacts. The vector representation of the protein pair is evaluated by each tree to determine if they are an interacting pair or a non-interacting pair. The forest tallies up all the input from the trees to come up with a final decision. The strength of this method is that it does not assume that domains interact independent of each other. This makes it so that multiple domains in proteins can be used in the prediction.
=== Immunocompetence === Evidence suggests that in many animal species, secondary sexual traits reflect male immunocompetence, the ability of an individual's immune system to resist and control pathogens or parasites. A study found that a single parasite-like immunological challenge, created via a nylon monofilament implant in the beetle, significantly reduced the sexual attractiveness and locomotor activity of males, but did not negatively affect their survival. When the inserts were removed, the majority of the males showed greater encapsulation responses of the implant, though some of the males seemed to have already chosen a terminal reproductive investment strategy. And thus, the majority of males invest in their immune system after the first challenge. A second immune challenge increased their attractiveness, but was found to significantly reduce locomotor activity of the males and increase their mortality. This represents a trade-off between pheromone production and energy required for activities such as immune system recovery and locomotor activity. When there was a third challenge implantation in the same males, there was a lower encapsulation rate of the nylon implants in more attractive males than the less attractive, showing that the males made no attempts to boost their immune system. The results suggest that males that become sexually attractive after the second immune challenge have a trade-off, where they sacrifice locomotor activity and do not energetically invest in immune system recovery.
Although bicalutamide monotherapy increases gonadotropin and sex hormone levels in men, this will not occur if bicalutamide is combined with an antigonadotropin such as a GnRH analogue, estrogen, or progestogen, as these medications maintain negative feedback on the HPG axis. NSAA monotherapy, including with bicalutamide, shows a number of tolerability differences from methods of androgen deprivation therapy that incorporate surgical or medical castration. For example, the rates of hot flashes, depression, fatigue, and sexual dysfunction are all much higher with GnRH analogues than with NSAA monotherapy. It is thought that this is because GnRH analogues suppress estrogen production in addition to androgen production, resulting in estrogen deficiency. In contrast, NSAA monotherapy does not decrease estrogen levels and in fact increases them, resulting in an excess of estrogens that compensates for androgen deficiency and allows for a preservation of mood, energy, and sexual function. Neurosteroids that are produced from testosterone like 3α-androstanediol and 3β-androstanediol, which are ERβTooltip estrogen receptor beta agonists and the former a potent GABAA receptor positive allosteric modulator, may also be involved. In the specific case of sexual dysfunction, an additional possibility for the difference is that without concomitant suppression of androgen production, blockade of the AR by the bicalutamide in the brain is incomplete and insufficient to markedly influence sexual function. Under normal circumstances, bicalutamide has no capacity to activate the AR.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.